The regulation of FasL expression - A distinguishing feature between monocytes and T lymphocytes/NK cells with possible implications for SLE

Journal of Clinical Immunology

Volumn 21, Issue 3, 2001, Pages 183-192

  Eneslätt, Kjell ^a   Rantapää Dahlqvist, Solbritt ^b   Uddhammar, Agneta ^b   Sundqvist, Karl Gösta ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Apoptosis; Lupus; Monocytes; T lymphocytes

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; FAS ANTIGEN; LIGAND; METALLOPROTEINASE INHIBITOR;

ARTICLE; CELL ISOLATION; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MONOCYTE; MONONUCLEAR CELL; NATURAL KILLER CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ADULT; ANTIGENS, CD95; ANTIGENS, SURFACE; APOPTOSIS; CASE-CONTROL STUDIES; CD4-CD8 RATIO; FAS LIGAND PROTEIN; FEMALE; HUMANS; KILLER CELLS, NATURAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MONOCYTES; PROTEASE INHIBITORS; T-LYMPHOCYTES;

EID: 0035031777     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011035115342     Document Type: Article

References (44)

1. 1. Scaffidi C, Kirchhoff S, Krammer PH, Peter ME: Apoptosis signaling in lymphocytes. Curr Opin Immunol 11:277-285, 1999
2. 2. McNally J, Yoo DH, Drappa J, Chu JL, Yagita H, Friedman SM, Elkon KB: Fas ligand expression and function in systemic lupus erythematosus. J. Immunol 159:4628-4636, 1997
3. 3. Lynch DH, Ramsdell F, Alderson MR: Fas and FasL in the homeostatic regulation of immune responses. Immunol. Today 16:569-574, 1995
4. + T cells. Nature 376:181-184, 1995
5. 5. Rathmell JC, Townsend SE, Xu JC, Flavell RA, Goodnow CC: Expansion or elimination of B cells in vivo: dual role for CD40-and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 57:319-329, 1996
6. 6. Nagata S: Fas and Fas ligand: A death factor and its receptor. Adv Immunol 57:129-144, 1994
7. 7. Leithäuser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, Möller P: Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 69:415-429, 1993
8. 8. Suda T, Okazaki T, Naito Y, Yokota T, Arai N, Ozaki S, Nakao K, Nagata S: Expression of the Fas ligand in the cells of T cell lineage. J Immunol 154:3806-3813, 1995
9. 9. Montel AH, Bochan MR, Hobbs JA, Lynch DH, Brahmi Z: Fas involment in cytotoxicity mediated by human NK cells. Cell Immunol 166:236-246, 1995
10. 10. Tanaka M, Itai T, Adachi M, Nagata S: Downregulation of Fas ligand by shedding. Nature Med 4:31-36, 1998
11. 11. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC: A role for CD95 ligand in preventing graft rejection. Nature 377:630-632, 1995
12. 12. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189-1192, 1995
13. 13. Cohen PL, Eisenberg RA: The lpr and gld genes in systemic autoimmunity: life and death in the Fas lane. Immunol Today 13:427-428, 1992
14. 14. Nagata S, Suda T: Fas and Fas ligand: lpr and gld mutations. Immunol Today 16:39-43, 1995
15. 15. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314-317, 1992
16. 16. Emlen W, Niebur J, Kadera R: Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus, J Immunol 152:3685-3692, 1994
17. 17. Utz PJ, Hottelet, Schur PH, Anderson P: Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus. J Exp Med 185:843-854, 1997
18. 18. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middelton LA, Lin AY, Strober W, Lenardo MJ, Puck JM: Dominant interfering Fas gene mutations impair apoptosis in a human lymphoproliferative syndrome. Cell 81:935-946, 1995
19. 19. Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB: Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 335:1643-1649, 1996
20. 20. Rieux-Laucat F, Le Deist F, Hivroz, Roberts IAG, Debatin KM, Fischer A, de Villartay JP: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268: 1347-1349, 1995
21. 21. Mysler E, Bini P, Drappa J, Ramos P, Friedman SM, Krammer PH, Elkon KB: The APO-1/Fas protein in human systemic lupus erythematosus. J Clin Invest 93:1029-1034, 1994
22. 22. Mariani SM, Matiba B, Bäumler C, Krammer PH: Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur J Immunol 25:2303-2307, 1995
23. 23. Cascino I, Fiucci G, Papoff G, Ruberti G: Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 154:2706-2713, 1995
24. 24. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD: Protection from Fas mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759-1762, 1994
25. 25. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S: Membrane Fas ligand kills human pheripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 186:2045-2050, 1997
26. 26. Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H: Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arth Rheum 40:1126-1129, 1997
27. 27. Tanaka M, Suda T, Takahashi T, Nagata S: Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J 14:1129-1135, 1995
28. 28. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H: Metalloproteinase-mediated release of human Fas ligand. J Exp Med 182:1777-1783, 1995
29. 29. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arth Rheum 25:1271-1277, 1982
30. 30. Hochberg MC: Updating the American College of Rheumatology revised criteria for classification of systemic lupus erythematosus. Arth Rheum 40:1725, 1997
31. 31. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis studies in SLE. Arth Rheum 35:630-640, 1992
32. 32. Gladman DD, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly J, Hay E, Isenberg D, Jones J, Kalunian K, Maddison P, Nived O, Petri M, Richter M, Sanches-Guerrero J, Snaith M, Sturfelt G, Symmons D, Zoma A: The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus, Arth Rheum 39:363-369, 1996
33. 33. Chomczynski P, Sacchi N: Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 152:156-159, 1987
34. 34. Galon J, Moldovan I, Galinha A, Provost-Marloie MA, Kaudewitz H, Roman-Roman S, Fridman WH, Sautes C: Identification of the cleavage site involved in production of plasma soluble Fc gamma receptor type III (CD16). Eur J Immunol 28:2101-2107, 1998
35. 35. Gearing AJH, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, Leber TM, Mangan M, Miller K, Nayee P, Owen K, Patel S, Thomas W, Wells G, Wood LM, Woolley K: Processing of tumor necrosis factor-α precursor by metalloproteinases. Nature 370:555-557, 1994
36. 36. Brown SB, Savill J: Phagocytosis triggers macrophage release of Fas ligand and induces apoptosis of bystander leukocytes. J Immunol 162:480-485, 1999
37. 37. Heidenreich S: Monocyte CD14: A multifunctional receptor engaged in apoptosis from both sides. J Leukoc Biol 65:737-743, 1999
38. 38. Birkedal-Hansen H, Moore WGI, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA: Matrix metalloproteinases: A review. Crit Rev Oral Biol Med 4:197-250, 1993
39. 39. Mitsiades N, Poulaki V, Kotoula V, Leone A, Tsokos M: Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase. Am J Pathol 153:1947-1956, 1998
40. 40. Powell WC, Fingleton B, Wilson CL, Boothby M, Matrisian LM: The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol 9:1441-1447, 1999
41. 41. Hill GE: Cardiopulmonary bypass-induced inflamation: Is it important? J Cardiothorac Vasc Anesth 12:21-25, 1998
42. 42. Kiener PA, Davis PM, Starling GC, Mehlin C, Klebanoff SJ, Ledbetter JA, Liles WC: Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. J Exp Med 185:1511-1516, 1997
43. 43. Kiener PA, Davis PM, Rankin BM, Klebanoff SJ, Ledbetter JA, Starling GC, Liles WC: Human monocytic cells contain high levels of intracellular Fas ligand: rapid release following cellular activation. J Immunol 159:1594-1598, 1997
44. + T cells to Fas-mediated apoptosis. Cancer Immunol Immunother 49:335-345, 2000